The GPR1-binding peptide was evidenced to inhibit the triple-negative breast carcinoma [136] and improve LPS-Induced depressant-like behaviors and ovarian functions [42] in vivo. This evidence concerns the gene CMKLR2 and triple-negative breast carcinoma.